Concurrent NRAS and ASXL1 mutations associate with poor prognosis in CMML. (A) Percentages of CMML patients with NRAS mutation in patients with MT or WT ASXL1 are shown. P value was determined using the χ2 test. (B) Overall survival and leukemia-free survival of CMML patients stratified on the basis of ASXL1 and NRAS mutation status. P values were determined using the log-rank test.
Figure 1.

Concurrent NRAS and ASXL1 mutations associate with poor prognosis in CMML. (A) Percentages of CMML patients with NRAS mutation in patients with MT or WT ASXL1 are shown. P value was determined using the χ2 test. (B) Overall survival and leukemia-free survival of CMML patients stratified on the basis of ASXL1 and NRAS mutation status. P values were determined using the log-rank test.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal